CBG hand Sanitizer Complements CBD Product RangeVancouver, British Columbia – (Accesswire) – July 10, 2020 – Stillcanna Inc. (OTC:SCNNF) (CSE:STIL) (FRANKFURT:A2PEWA) (“STIL” or the “Company”), is pleased to announce that its planned strategic acquisition, the Sativa Group PLC, one of the United Kingdom’s (UK) first medical Cannabis Companies has announced record sales for the month of June.

In complementing the Goodbody brands already expansive CBD product range with a UK compliant hand sanitizer and a CBG based hand sanitizer, both Goodbody Botanicals and Goodbody Wellness realized increased sales volumes. By addressing current market opportunities through new product development, record sales have been achieved in the month of June.
Wide ranges of business demographics including restaurants and airlines, hotels groups and retailers have embraced the Goodbody sanitizer program to safeguard and protect their customers and staff.

Henry Lees-Buckley, Chief Executive Officer of Sativa, said; “Through our corporate customers we have achieved very strong hand sanitizer sales to complement our existing CBD sales, which have resulted in a record month for the Group. We’re very pleased to reach this milestone during these difficult retail trading conditions”.
“Together Stillcanna and the Sativa Group address many vertical markets within the Cannabis landscape,” stated Jason Dussault CEO of Stillcanna. “The combined entities strengths, industry knowledge and wide product range have resulted in a record month for the group in one of the most challenging times in the market. As a combined corporate group we look forward to continued growth in the new normal.”

About Sativa Group PLC
The Sativa Group PLC joined the UK’s NEX market in March 2018 as the UK’s first medicinal cannabis investment vehicle. The business evolved to focus on the development of an operational business capitalizing on its first-mover advantage. This change transitioned the Company from an investment Company to an operating Company at the forefront of both the CBD wellness and medicinal cannabis sectors in the UK.

About Stillcanna Inc.
Stillcanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences Company focused on the large scale manufacturing of CBD in Europe. The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, a multi-generational hemp agricultural firm that is expected to increase the Company’s market share in the European CBD industry.

On Behalf of the Board
Jason Dussault, CEO

CONTACT:
[email protected]

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Stillcanna’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

The forward-looking information and forward-looking statements contained herein include but are not limited to information concerning that as a combined corporate group we look forward to continued growth in the new normal. The Company may in fact not grow within the foreseeable future. It is also possible that for reasons unknown that the acquisition of the Sativa Group may not complete.

Although Stillcanna believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements.

The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and Stillcanna does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
RelatedStillcanna Signs Definitive Agreement to Acquire Sativa Group PLC of the United Kingdom|Stillcanna’s Romania Extraction Facility Receives Final Operational Permit and Stillcanna Appoints New President of European Operations|Stillcanna Offers CBD White Label Services in Europe